Abstract
Antiangiogenic gene transfer has the potential to be more efficacious than protein-based therapies or pharmacotherapies for the control of solid tumor growth, invasion and metastasis. For a sustained antiangiogenic effect, a vector capable of long-term expression without vector-associated immunity or toxicity is advantageous. The present study evaluated the potential of a recombinant adeno-associated virus-2 (rAAV) encoding the human soluble FMS-like tyrosine kinase receptor 1 (sFlt-1), which functions by both sequestering vascular endothelial growth factor (VEGF) and forming inactive heterodimers with other membrane-spanning VEGF receptors, in vitro and in vivo. Results indicated significant growth inhibitory activity of the transgenic factor in a human umbilical vein endothelial cell proliferation assay in vitro and protection against the growth of an angiogenesis-dependent human ovarian cancer cell line, SKOV3.ip1, xenograft in vivo with increased disease-free survival. Stable expression of the secretory factor and transgene persistence were confirmed by immunohistochemistry and in situ hybridization analyses, respectively. Increased therapeutic effects on both the growth index of the implanted tumor cells and tumor-free survival also correlated with an increasing dose of the vector used. These studies indicate that rAAV-mediated sFlt-1 gene therapy may be a feasible approach for inhibiting tumor angiogenesis, particularly as an adjuvant/therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman J . The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3: 65–71.
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27–31.
Gyorffy S, Palmer K, Podor TJ, Hitt M, Gauldie J . Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol. 2001; 166: 6212–6217.
Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996; 70: 8098–8108.
Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997; 3: 306–312.
Snyder RO . Adeno-associated virus-mediated gene delivery. J Gene Med. 1999; 1: 166–175.
Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP . Adeno-associated virus for cancer gene therapy. Adeno-associated virus for cancer gene therapy. Cancer Res. 2001; 61: 6313–6321.
Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002; 62: 7124–7129.
Kendall RL, Wang G, Thomas KA . Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996; 226: 324–328.
Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. 2003; 194: 119–124.
Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas. 2002; 25: 122–129.
Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61: 5407–5414.
Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W . VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer. 2002; 97: 163–167.
Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res. 2003; 9: 2701–2710.
Mahasreshti PJ, Navarro JG, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res. 2001; 7: 2057–2066.
Samulski RJ, Chang LS, Shenk TA . Recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 1987; 61: 3096–3101.
Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Nat Acad Sci USA. 1998; 95: 8795–8800.
Zolotukhin S, Byrne B, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy. 1999; 6: 973–985.
Ponnazhagan S, Erikson D, Kearns WG, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther. 1997; 8: 275–284.
Ponnazhagan S, Mukherjee P, Yoder MC, et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene. 1997; 190: 203–210.
Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas Jr M . Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol. 2002; 76: 12900–12907.
Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther. 2001; 4: 223–231.
Wick MR, Siegal GP . Monoclonal Antibodies in Diagnostic Immunohistochemistry. New York: Marcel Dekker; 1988; 18–19.
Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 1998; 85: 4212–4223.
Miao CH, Nakai H, Thompson AR, et al. Non-random transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol. 2000; 74: 3793–3803.
Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 1994; 8: 2683–2690.
Shimizu H, Miyazaki M, Wakabayashi Y, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol. 2001; 34: 683–689.
Yang W, Arii S, Mori A, et al. sFlt-1 gene-transfected fibroblasts: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res. 2001; 61: 7840–7845.
Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Therapy. 2001; 12: 1299–1310.
Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy. 2002; 9: 320–326.
Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE . Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy. 2002; 9: 804–813.
Hasumi Y, Mizukami H, Urabe M, et al. Soluble Flt-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002; 62: 2019–2023.
Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 1997; 94: 5804–5809.
Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy. 1998; 5: 40–49.
Bohl D, Bosch A, Cardona A, Salvetti A, Heard JM . Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood. 2000; 95: 2793–2798.
Watchko J, O'Day T, Wang B, et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002; 13: 1451–1460.
Lu YY, Wang LJ, Muramatsu S, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF and its delivery to spinal motoneurons by retrograde transport. Neurosci Res. 2003; 45: 33–40.
Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000; 24: 257–261.
Folkman J . Anti-angiogenic gene therapy. Proc Natl Acad Sci USA. 1998; 95: 9064–9066.
Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997; 76: 1221–1227.
Kong HL, Crystal RG . Gene therapy strategies for tumor angiogenesis. J Natl Cancer Inst. 1998; 90: 273–286.
Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61: 5407–5414.
Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP . Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999; 5: 2963–2970.
Soffer SZ, Moore JT, Kim E, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001; 36: 1177–1181.
Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus-2-mediated anti-angiogenic gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004; 64: 1781–1787.
Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 1999; 283: 88–91.
Rivera VM, Ye X, Courage NL, et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA. 1999; 15: 8657–8662.
Acknowledgements
This work was supported by a Career Development Award from NIH-Ovarian SPORE Grant CA83591, NIH Grants CA90850, CA98817, AR46031 and US Army Department of Defense Grants BC010494 and PC020372.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahendra, G., Kumar, S., Isayeva, T. et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther 12, 26–34 (2005). https://doi.org/10.1038/sj.cgt.7700754
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700754
Keywords
This article is cited by
-
Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice
Cancer Gene Therapy (2011)
-
Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors
Cancer Gene Therapy (2007)
-
Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway
Gene Therapy (2007)
-
Genetic strategies for brain tumor therapy
Cancer Gene Therapy (2006)
-
Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors
Cancer Gene Therapy (2006)